Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC-3S in HIV-1 infected patients
NCT02390466Phase 2Unknown
- Sponsor
- InnaVirVax
- Start
- Apr 2015
- Primary completion
- Apr 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VAC-3S in human immunodeficiency virus infection (HIV), sponsored by InnaVirVax. Primary endpoint: Number of patients who tolerated 3 vaccinations with VAC-3S. Status: unknown.
02
Drugs
VAC-3S
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02390466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390466.